Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep608 | Pituitary and Neuroendocrinology | ECE2020

Metabolism of glucose in patients with acromegaly treated with Pegvisomant and/or Pasireotide LAR after resistance to first generation somatostatin receptor ligands

Chiloiro Sabrina , Giampietro Antonella , Bianchi Antonio , Maria Formenti Anna , Maya Fleseriu Cara , Pontecorvi Alfredo , Giustina Andrea , De Marinis Laura

Introduction: Acromegaly (Acro) is characterized by insulin sensitivityreduction, glucose intolerance (IGT) and diabetes mellitus (DM2 in 15%–38% of patients). Studies that investigated action of medical therapies for acro on glucose metabolism, didn’t provide conclusive data. Association between blood glucose (BG) levels and serum IGF-I levels in patients with DM2 and acro has been suggested, however,IGF-I levels and hemoglobin A1c (HbA1c) correlation is still con...

ea0070aep662 | Pituitary and Neuroendocrinology | ECE2020

Predictors of response to medical therapy with pegvisomant and pasireotide lar in SRLs-resistant acromegaly

Chiloiro Sabrina , Giampietro Antonella , Bianchi Antonio , Mirra Federica , Donfrancesco Federico , Maya Fleseriu Cara , Lauretti Liveraba , Anile Carmelo , Gessi Marco , Rindi Guido , Pontecorvi Alfredo , Fleseriu Maria , Giustina Andrea , De Marinis Laura

Background: Pegvisomant(PegV) and Pasireotide LAR(Pasi) are commonly used in acromegaly patients resistant to first-generation SRLs. Predictors of response to therapy with PegV and Pasi in this subset of patients are still unclear. These findings may be useful in choosing the most appropriate therapeutic option for the personalized treatment of patients affected by more aggressive disease. We aimed to identify individual predictors of responses.Methods: ...